Original Research Article

Clinical and radiological parameters among COVID deaths in a tertiary care COVID hospital

Ramakrishna Rachakonda1,* , DVC Nagasree2, Chakradhar Bolleddu1, Kironmagi Abbhri1, Bhavanarayana Jannela1, Omar Pasha1, Aruna Talatam1

1 Dept. of Pulmonary Medicine, NRI Medical College, Chinnakakani, Guntur, Andhra Pradesh, India
2 Dept. of Ophthalmology, NRI Medical College, Guntur, Andhra Pradesh, India

ARTICLE INFO

Article history:
Received 08-02-2021
Accepted 20-02-2021
Available online 25-02-2021

Keywords:
COVID 19
Corona
CORADS Score
Lung burden
CT severity Index
Happy hypoxia
MMRC scale

ABSTRACT

Background: A total of 10682 patients were admitted in our tertiary care COVID hospital from April 2020 to January 2021. 419 patients died with a mortality rate of 3.92%. We have analysed 241 deaths that have taken place till 10th September 2020.

Methodology: We studied the history, symptomatology, HRCT chest, comorbidities, duration of hospital stay and special drugs administered along with the type of oxygen therapy.

Results: 88% of patients have more than 30% lung burden by HRCT. All the patients have a CO-RADS score of 4 or more. 81% of the patients have CT severity index of 15/25 or more. The CO-RADS classification is a standardized reporting system for patients with suspected COVID-19 infection developed for a moderate to high prevalence setting. 71% of patients expired within first five days of admission. 23% of patients died in 5 to 10 days of admission. 80% of patients presenting with < 80% SPO2 died in first five days. 77% of patients have single or multiple comorbidities. 23% of patients did not have any comorbidities. 34% of patients gave history of alcohol intake 41.9% have history of smoking. 38% of patients gave past history of lung disease. Shortness of breath, generalized weakness and cough were the common symptoms. Loss of smell was seen in 22% and loss of taste was seen in 25%. 81% of patients had more than 5 days of symptoms before admission. 19% had less than 5 days of symptoms. 73% of patients presented with Modified Medical research Council Scale Grade 3 or 4 breathlessness. Patients required oxygen in multiple forms. Only 5% of patients were put on mechanical ventilator. Remdesivir was given in 96% of patients. Anti IL6 Tocilizumab was given in 25%. Plasma therapy was given in 5%.

Conclusions: Patients dying of COVID-19 disease had significant CT scan changes suggestive of corona disease. Past history of lung disease was seen in only a third. Shortness of breath was the commonest symptom and majority of the patients presented with SPO2 of <90% and moderate to severe breathlessness.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Corona virus disease emanated from Wuhan City in China and spread throughout the world. In India the pandemic started from March 2020. Lock down observed in India decreased the spread of the disease and mortality. India witnessed more than 10 million cases in different states with a mortality of 1.47%. Severe viral Pneumonia and inflammatory storm associated with intravascular thrombosis is responsible for hypoxia and respiratory failure, ARDS and death.1,2 The disease has a short incubation period of around 5 to 12 days and is particularly severe in old people and people with comorbidities. 3

In this hospital based study we studied the clinical, radiological parameters, duration of hospital stay, comorbidities, history of smoking and alcohol intake, past history of lung disease, mode of oxygenation given and special drugs administered among the 241 patients who died because of COVID19.
2. Materials and Methods

A total of 10,682 COVID patients were admitted in NRI Medical College General Hospital from 1st April 2020 to 31st January 2021. We have analysed the deaths of 241 patients who died of COVID 19 disease up to September 2020. After having taken consent from the patient and families and approval from the ethical committee of the hospital, we conducted this study. There was a total death toll of 419 patients till January 31st 2021. Hospital based mortality was 3.92%. We studied the history, symptomatology, HRCT chest, comorbidities, duration of hospital stay and special drugs administered along with the type of oxygen therapy among these 241 patients.

3. Results

Analysis of 241 deaths taken place in the hospital up to 10th September 2020 from the beginning of the pandemic in March 2020

A total of 10682 COVID patients were admitted and among them 419 patients died up to 31 January 2021 with a mortality rate of 3.92%.

4. Discussion

We have analysed 241 deaths that took place in our tertiary care covid hospital. A total of 10691 patients were admitted and 419 deaths occurred among COVID 19 patients with a mortality rate of 3.92% among hospital admissions. 71% of the patients are males and 29% are females. 93% of patients belonged to age group of 30 and above. A third of deaths occurred in the age group of 60 to 70.71% of patients died in the first five days of admission and 94% of patients died within 10 days of admission. 77% of patients dying of COVID had associated comorbidities single or multiple. 23% of the patients did not have any comorbidities.

HRCT chest analysis of the patients who have died of COVID disease revealed 88% of patients had more than 30% of lung burden. CT severity index was was more than 15/25 in 82% of these patients. All the patients have CO-RADS 4 or more in CT scan chest. Ran Yang study revealed CT index correlated with severity of inflammation with 83% specificity and 94% sensitivity. Mathias Prokop etal., proposed CO-RADS score offers a five-point scale of suspicion for pulmonary involvement of COVID-19 at chest CT. Same view is endorsed by Lieweld, etal., Egyptian study of Mona A. F. Hafez et al., reiterated same fact.

72% of our patients died within first five days. Many of them were treated outside and were rushed to our centre with severe symptoms. Severity of symptoms hastened death among them. 99% of deaths occurred in first 10 days. 34% presented with SPO2 of less than 80% and 29% presented with SpO2 between 80 and 85%. 19% of patients had SPO2 between 85% and 90%. 82% of patients on the whole had SPO2 <90%. Xie et al., proved an association of mortality and hypoxia in COVIDd 19 patients. 77% of these patients have associated comorbidities single or multiple and 23% had none. Patients having higher age, of>65 years, Diabetes, Hypertension and cardiovascular disease have more severe disease and increased mortality. Smoking history was seen in 41.9% and history of alcohol intake was present in 34.43%.

Past history of Lung disease was present in 38% of patients and 62% had no history of lung disease. According to Leung et al., COPD patients have increased risk of severe COVID-19 pneumonia and poor outcome probably because of poor lung reserve and increased expression of ACE2 receptors in the small airways. Hong Huang et al., study revealed patients of ILD have worse prognosis compared to non ILD COVID-19 patients.

Breathlessness was present in all the patients followed by general weakness. Loss of smell and taste were found in less than 10% of patients. Hypoxemia without proportional signs of respiratory distress was found in our study also. This happy hypoxemia is due to hyperventilation secondary to leftward shift of Oxy-hemoglobin curve and alteration of hemoglobin by virus. Ventilation perfusion mismatch with increased alveolar dead space occurs in hypoxic patients. 73% of our patients presented with grade 3 and 4 of MMRC at the time of admission. 81% patients in our study had 5 to 15 days of symptoms before coming to the hospital.

High flow nasal oxygen and mechanical ventilation were provided for less than 5% of patients with each modality. Bilevel positive airway pressure and non-rebreathing masks were provided for a majority.

Apart from anticoagulant and corticosteroid therapy Remdesivir was provided for more than 96% of patients. Tocilizumab was given for 26% and Convalescent Plasma therapy was given for less than 5% of patients.

5. Conclusions

COVID pandemic started in our tertiary care centre in the month of April 2020 and peaked in August and September 2020 both in terms of hospital admissions and mortality. After that the pandemic has shown a decline with an overall mortality of 3.92%. Patients dying of COVID-19 disease had significant CT scan changes suggestive of corona disease. Past history of lung disease was seen in only a third. Shortness of breath was the commonest symptom and majority of the patients presented with SPO2 of <90% and moderate to severe breathlessness. All modalities oxygenation were provided except ECMO. Ventilation and HFN0 were provided for <5%. Remdesivir was given for a majority. Limited number of patients received Tocilizumab and Convalescent Plasma.

6. Acknowledgement

None.
Table 1: Gender Distribution:

| Gender     | No. of Patients | Total No. of Deaths | No. | Percentage |
|------------|-----------------|---------------------|-----|------------|
| Male       | 171             | 241                 | 71% |            |
| Female     | 70              | 241                 | 29% |            |

Table 2: Age Distribution

| Age Group | No. of Patients | Percentage |
|-----------|-----------------|------------|
| 0-10      | 01              | 0.41%      |
| 11-20     | 01              | 0.41%      |
| 21-30     | 03              | 1.23%      |
| 31-40     | 12              | 4.92%      |
| 41-50     | 30              | 12.3%      |
| 51-60     | 57              | 23.37%     |
| 61-70     | 81              | 33.21%     |
| 71-80     | 44              | 18.04%     |
| 81 and above | 12         | 4.92%      |

Table 3: Duration of Hospital stay

| Duration of Hospital Stay | No. of Patients | Percentage |
|---------------------------|-----------------|------------|
| 1-5 days                  | 172             | 71.36%     |
| 6-10 days                 | 55              | 22.82%     |
| 11-15 days                | 09              | 3.73%      |
| 16-20 days                | 04              | 1.66%      |
| >20 days                  | 01              | 0.41%      |

Table 4: Comorbidities among COVID deaths

| Comorbidity                                                      | No. of Patients | Percentage |
|-----------------------------------------------------------------|-----------------|------------|
| Diabetes Mellitus + Hypertension + Chronic kidney Disease       | 10              | 4.15%      |
| Diabetes Mellitus + Hypertension + Cerebrovascular Accident     | 03              | 1.24%      |
| Chronic Kidney Disease + Chronic Lung Disease                   | 02              | 0.82%      |
| Diabetes Mellitus + Hypertension + Coronary Artery Disease      | 07              | 2.90%      |
| Diabetes Mellitus + Hypertension                                | 32              | 13.27%     |
| Hypertension                                                    | 37              | 19.51%     |
| Hypothyroidism                                                  | 08              | 3.31%      |
| Diabetes Mellitus + Coronary Artery disease                     | 09              | 3.73%      |
| Diabetes Mellitus                                               | 124             | 51.45%     |
| Chronic Lung Disease                                            | 03              | 1.24%      |
| Chronic Kidney Disease                                          | 28              | 11.61%     |
| No Comorbidity                                                  | 55              | 22.82%     |

Table 5: Lung Burden involvement by HRCT scan Chest

| Lung Burden | No. of Patients | Percentage |
|-------------|-----------------|------------|
| 10-20%      | 03              | 1%         |
| 20-30%      | 27              | 11%        |
| 30-40%      | 36              | 15%        |
| 40-50%      | 67              | 28%        |
| 50-60%      | 43              | 18%        |
| 60-70%      | 36              | 15%        |
| >70%        | 29              | 12%        |

Table 6: CO-RADS score by CT Chest

| CO-RADS Score | No. of Patients | Percentage |
|---------------|-----------------|------------|
| CORADS 4      | 60              | 25%        |
| CO-RADS 5     | 76              | 32%        |
| CO-RADS 6     | 105             | 43%        |

Table 7: CT Severity Index

| CT severity | No. of patients | Percentage |
|-------------|-----------------|------------|
| 0-7/25      | 02              | 0.82%      |
| 8-15/25     | 42              | 17.42%     |
| 15-25/25    | 96              | 39.83%     |
| 20-25/25    | 101             | 41.9%      |
### Table 8: Comparison of No. of days of Hospital stay and SPO2 at admission

| No. of days of Hospital Stay | Total No. of Patients | SPO2 at admission <80% | SPO2 80-85% | SPO2 85-90% | SPO2 90-95% | SPO2 >95% |
|-----------------------------|-----------------------|------------------------|-------------|-------------|-------------|------------|
| 1-5 days                    | 172 (71.36%)          | 66 (27.38%)            | 54 (22.45)  | 42 (17.43%) | 9 (3.73%)   | 1 (0.41%)  |
| 6-10 days                   | 55 (22.82%)           | 12 (4.98%)             | 14 (5.80%)  | 16 (6.64%)  | 8 (3.32%)   | 5 (2.07%)  |
| 11-15 days                  | 9 (3.73%)             | 3 (1.23%)              | 2 (0.83%)   | 1 (0.41%)   | 1 (0.41%)   | 2 (0.83%)  |
| 16-20 days                  | 04 (1.66%)            | 1 (0.41%)              | 1 (0.41%)   | 1 (0.41%)   | 0           | 0          |
| >20 days                    | 1 (0.41%)             | 0                      | 0           | 1 (0.41%)   | 0           | 0          |

### Table 9: Comparing the SPO2 at Admission and Hospital stay:

| SPO2 at Admission | Hospital stay 1-5 days | 6-10 days | 11-15 days | 16 – 20 days | >20 days |
|-------------------|------------------------|-----------|------------|--------------|----------|
| <80%              | 66                     | 12        | 3          | 1            | 0        |
| 80-85%            | 54                     | 14        | 2          | 1            | 0        |
| 85-90%            | 42                     | 16        | 1          | 1            | 1        |
| 90-95%            | 9                      | 8         | 1          | 1            | 0        |
| >95%              | 1                      | 5         | 2          | 0            | 0        |
| Total             | 172                    | 55        | 9          | 4            | 1        |

### Table 10: H/O Alcohol Intake

| Habit of Alcohol Intake | No. of Patients | Percentage | Total Number of patients |
|------------------------|----------------|------------|--------------------------|
| Yes                    | 83             | 34.43%     | 241                      |
| No                     | 158            | 65.56%     | 241                      |

### Table 11: Smoking History

| Smoking History | No. of patients | Percentage | Total No. of Patients |
|-----------------|-----------------|------------|-----------------------|
| Yes             | 101             | 41.9%      | 241                   |
| No              | 140             | 58.09%     | 241                   |

### Table 12: Past History of Lung Disease

| Lung Disease   | No. of patients | Percentage |
|----------------|-----------------|------------|
| COPD           | 29              | 12%        |
| ILD            | 15              | 6.2%       |
| Bronchiectasis | 14              | 5.8%       |
| Bronchial Asthma | 28          | 11.6%      |
| Tuberculosis   | 5               | 2%         |
| No Lung Disease | 150             | 62.24%     |

### Table 13: Complaints at the time of admission

| Symptom       | No. of Patients | Percentage |
|---------------|-----------------|------------|
| SOB           | 241             | 100%       |
| Fever         | 82              | 34.02%     |
| Chest Pain    | 56              | 23.23%     |
| Cough         | 96              | 39.83%     |
| Generalized weakness | 204        | 84.6%      |
| Palpitation   | 108             | 44.8%      |
| Loss of smell | 54              | 22.41%     |
| Throat pain   | 80              | 33.19%     |
| Loss of taste | 60              | 24.89%     |
| Anxiety       | 154             | 63.9%      |
Table 14: MMRC Scale of SOB at the time of Admission

| MMRC Grading | No. of Patients | Percentage |
|--------------|----------------|------------|
| Grade I      | 21             | 8.71%      |
| Grade II     | 45             | 18.67%     |
| Grade III    | 80             | 33.19%     |
| Grade IV     | 95             | 39.41%     |

Table 15: Duration of Symptoms before Admission

| Duration of symptoms | No. of Patients | Percentage |
|----------------------|----------------|------------|
| 1-5 days             | 45             | 18.67%     |
| 5-10 days            | 60             | 24.89%     |
| 10-15 days           | 136            | 56.43%     |

Table 16: Mode of Oxygenation

| Type of Oxygenation | No. of Patients | Percentage |
|---------------------|----------------|------------|
| Oxygen Mask         | 44             | 18.25%     |
| NRBM                | 71             | 29.46%     |
| Venturi Mask        | 51             | 21.16%     |
| BIPAP               | 102            | 42.32%     |
| HFNO                | 12             | 4.97%      |
| Mechanical ventilation | 12           | 4.97%      |

Table 17: Special drugs given along with Steroid and Low Molecular weight Heparin

| Drug                   | No. of patients | Percentage |
|------------------------|-----------------|------------|
| Remdesivir             | 232             | 96.26%     |
| Tocilizumab            | 64              | 25.55%     |
| Plasma Therapy         | 12              | 4.97%      |

7. Source of Funding

No financial support was received for the work in this manuscript.

8. Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. Garima S. Fatality in COVID 19: an overview of causes of death and organ involvement. *Int J Adv Med*. 2020;7(7):1190–3.
2. Sharma A, Sinha S, Kale K. Causes of deaths in COVID-19 patients. *Int J Res Pharm Sci*. 2020;11(SPL1):416–9. [doi:10.4103/ijrps.ijrps1.2801]
3. Wiersinga WJ. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review. *AMA*. 2020;324(8):782–93.
4. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. *Radiol: Cardiothoracic Imaging*. 2020;2(2).
5. Prokop M, Co-Rads. A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. *Radiol*. 2020;296(2).
6. Lieveld AWE, Azijli K, Teunissen BP, van Haften R, Kootte RS, van den Berk I, et al. Chest CT in COVID-19 at the ED: Validation of the COVID-19 Reporting and Data System (CO-RADS) and CT Severity Score. *Chest*. 2020;[doi:10.1016/j.chest.2020.11.029]
7. Hafez MAF. The mean severity score and its correlation with common computed tomography chest manifestations in Egyptian patients with COVID-19 pneumonia. *Egypt J Radiol Nucl Med*. 2020;5.
8. Xie J, Covassini N, Fan Z, Singh P, Gao W, Li G, et al. Association Between Hypoxemia and Mortality in Patients With COVID-19. *Mayo Clin Proc*. 2020;95(6):1138–47. [doi:10.1016/j.mayocp.2020.04.004]
9. Baigain KT, Badal S, Baigain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. *Am J Infect Control*. 2021;49(2):238–46. [doi:10.1016/j.ajic.2020.06.213]
10. Leung JIM. COVID-19 and COPD. *Eur Respir J*. 2020;56.
11. Huang H, Zhang M, Chen C, Zhang H, Wei Y, Tian J, et al. Clinical Characteristics of Covid 19 in Patients with preexisting ILD: A retrospective study in single center in Wuhan, China. *J Med Virol*. 2020;13. [doi:10.1002/jmv.26174]
12. Dhont S. The pathophysiology of ‘happy’ hypoxemia in COVID-19. *Respir Res*. 2020;198.
13. Clinical management protocol: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division), Version 2020.

Author biography

Ramakrishna Rachakonda, Professor and HOD

DVC Nagasree, Professor

Chakradhar Bolleddu, Assistant Professor

Kironmagi Abbhri, Assistant Professor

Bhavanarayana Jannela, Post Graduate
